GleamWall
中文EN

RNTX Rein Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1420565 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY15.6%
TTM EPS YoY48.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-100.5%
ROA-87.9%
ROIC (approx.)-85.7%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets11.2%
Debt / equity0.00x
Current ratio6.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.45x
Accruals ratio-48.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$11.03M$14.25M
SG&A expense$10.90M$13.86M
Operating income-$50.63M-$65.11M
Income tax-$712,000-$1.54M
Net income-$49.87M-$62.88M
EBITDA-$50.63M-$65.05M
EPS (basic)-1.96-3.51
EPS (diluted)-1.96-3.51
Dividends declared per share0.000.00
Weighted avg. shares (diluted)25.44M17.94M
Balance sheet
Cash & equivalents$3.21M$12.87M
Short-term investments$0—
Current assets$4.33M$13.66M
PP&E, net$0$1,000
Goodwill$6.33M$6.33M
Intangibles$13.50M$42.20M
Total assets$24.16M$62.19M
Current liabilities$6.18M$5.75M
Total liabilities$7.24M$7.80M
Shareholders' equity$16.92M$54.39M
Shares outstanding27.55M21.67M
Cash flow statement
Operating cash flow-$19.36M-$22.29M
Investing cash flow—$0
Financing cash flow$9.76M$17.82M
Depreciation & amortization$1,000$63,000
Stock-based compensation$2.22M$1.12M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.